Trial
NCT06055374
A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Repeated-dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Brexogen Inc.
Collaborators
—
Condition
Atopic Dermatitis
Intervention
BxC-I17e
Why stopped
This study was integrated into BRE-AD01-001 study
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-08-09